Sized to Perfection
Breaking news
Osteo-Pharma and Emultech announce joint venture
Emultech and Osteo-Pharma today announced a joint venture to develop what could be the first disease-modifying treatment for osteoarthritis of the knee. The joint venture, to be called Bone-Tech, brings together Osteo-Pharma’s novel combination drug therapy for the local treatment of osteoarthritis with Emultech’s world leading microfluidics’ microspheres technology. Bone-Tech’s patented OsteoActivator™ microspheres treatment promises to be the first and only extended-release treatment targeting subchondral bone remodelling for patients suffering from osteoarthritis-related pain and disability.
Advantages of microfluidic emulsification
- Monodisperse nano- and microparticles of all sizes and properties
- High drug loading through high encapsulation efficiencies
- Safe encapsulation of proteins due to gentle nature of the process
- Improved injectability through uniformity of particles
- Broad range of polymer solutions
- Minimal waste of expensive raw materials since no sieving is required
Partner with Emultech to improve your products
- Patented solutions add protection for your product
- Experts in controlled release drug delivery from days to weeks to months
- Injectable and other applications from dermal fillers to embolization to drug delivery
- The only continuous and scalable microfluidics system
- Full range of services in formulation, development and manufacturing
- Flexible partnerships from products and solutions provider to joint ventures
From feasibility to clinic
Supports discovery, to clinical, to commercial production
Applications
A wide range of particles can be produced with microfluidic emulsification with sizes ranging from nano to micro. Emultech’s technology platform supports oil-in-water and water-in-oil emulsification as well as hydrodynamic flow focussing.
| Unloaded | Loaded | |
|---|---|---|
| Microspheres |
Medical devices (Fillers, Embolization, Wound healing) |
Controlled release small molecules |
| Hydrospheres |
Controlled release biologics |
|
| Polymeric nanoparticles |
Targeted delivery small molecules |
Emultech’s Microfluidic Emulsification
On a unique small chip with up to 100 identical channels emulsion droplets are continuously produced in a fully controlled, predictable and scalable manner.
Mission
Our mission is to create highly differentiated products featuring our proprietary monodisperse microspheres.
Vision
We bring significant value to our global pharma and medical device partners through a cost efficient and risk minimized pathway, designing injectable and other products with superior performance and consistency.
The latest news and events
Read all about what’s happening at Emultech. The latest news, job openings and upcoming events.
Osteo-Pharma and Emultech announce joint venture
Osteo-Pharma and Emultech announce joint venture to develop First-In-Class disease modifying treatment for Osteoarthritis AMSTERDAM, November 17, 2021 (Newswire.com) – Emultech and Osteo-Pharma today announced a joint venture to develop what could be the first disease-modifying treatment for osteoarthritis of the knee. The joint venture, to be called Bone-Tech, brings together Osteo-Pharma’s novel combination drug therapy for the local treatment of […]
Emultech sponsors CRS’s “New technologies for drug delivery systems” session
Emultech will attend the CRS 2021 on July 25-29, 2021. The tech session on “New technologies for drug delivery systems” will be sponsored by us. You can visit us at boot NW05. We hope to see you there! https://2021.controlledreleasesociety.org/new-technologies-for-drug-delivery-systems.html
Emultech retains Scott Fleming as COO and expands scientific staff
Scott Fleming joins Emultech as Chief Commercial Officer to expand and accelerate growth Mr. Fleming brings nearly 30 years experience in the pharmaceutical and drug delivery industries, with a background that includes management & technology consulting, entrepreneurship and executive commercial positions in both large and specialty pharmaceutical companies. Mr. Fleming co-founded MicroDose Therapeutx, a drug […]
Contact
Contact us now to arrange for a rapid evaluation of your formulation. Interested in meeting Emultech? Check out our Media page to see where you can find us next.